Description
This report considers the markets for therapeutic cardiovascular devices, such as prosthetic valves, pacemakers, stents, support devices, ICDs, VADs, and TAHs, in the United States as broken down into four major segments:
- cardiomyopathy/congestive heart failure
- arrhythmias
- arteriosclerosis (coronary artery disease), and
- valvular heart disease
While there are other cardiovascular conditions that remain significant in the American population, e.g., stroke and myocardial infarction, these four conditions present the core conditions that lead to more serious cardiovascular accidents and death and present the opportunity for the therapeutic device market.
This report discusses the market for specific therapeutic device products for the cardiovascular market in terms of their potential in the population in the United States as a whole and in the 45-years-old and older subsegment of the U.S. population through 2014. Market potential is used as opposed to a rehash of experienced and projected revenues for several reason for this:
- A large number of therapeutic applications for cardiovascular disease are currently in development and are based on advanced technology in therapeutic device design and development.
- Because much of the potential use of new therapeutics is not associated with commonly available databases, it is often impossible to determine their level and type of their application in the growing market environments.
- The status of the current market in terms of revenues is misleading of the potential market as a whole. It does not allow for the understanding of the potential of unmet need, which will be discussed in the various sections of this report, and is in no way reflected by the current revenue picture for therapeutic cardiovascular devices.
As a result, we believe these market assessments provide a more realistic view of the opportunities available to those who are engaged or interested in addressing them. The key is in understanding how much of this potential has actually been realized and how much is unmet need.
The analysis presented in this report is based on data from a combination of company, government, industrial, institutional and private sources. It includes information from extensive literature reviews, as well as interviews and discussions with experts in the field, including experts in cardiology, cardiac surgery, vascular surgery, internal medicine, and gerontology, as well as research scientists, and business development and marketing managers within the medical devices, industries. The analyses are based on:
- The current and expected levels of research and development for age-related cardiovascular disease therapeutic devices
- The general trends in population demographics; epidemiology of cardiomyopathy/congestive heart failure, arrhythmia, arteriosclerosis, and valvular heart disease; and other factors that affect those trends
- The trends in approaches to cardiovascular disease prevention
- Costs analysis based on studies of actual research and projected costs of new cardiovascular disease therapeutic products by those engaged in their development.
Table of Contents
CHAPTER ONE: Executive Summary
- Background
- Cardiomyopathy/Congestive Heart Failure
- Left Ventricular (LV) Failure
- Right Ventricular (RV) Failure
- Systolic Dysfunction
- Diastolic Dysfunction
- High Output Failure
- Arrhythmias
- Arteriosclerosis (Coronary Artery Disease)
- Heart Valve Disease
- Scope and Methodology
- Size and Growth of Market
- Competitive Picture
- Market Trends and Factors
CHAPTER tWO: Overview of Cardiovascular Disease
- Background
- Aneurysm
- Arrhythmias
- Athletic Heart Syndrome
- Cardiac Arrest
- Cardiac Tumors
- Cardiomyopathy
- Congenital Heart Disease
- Congestive Heart Failure
- Types of Heart Failure
- Left Ventricular (LV) Failure
- Right Ventricular (RV) Failure
- Systolic Dysfunction
- Diastolic Dysfunction
- High Output Failure
- Theories of Heart Failure
- Hemodynamic Response Theory
- Neurohormonal Response Theory
- Renal Response Theory
- Coronary Artery Disease
- Endocarditis
- Infective Endocarditis
- Subacute bacterial endocarditis (SBE)
- Acute bacterial endocarditis (ABE)
- Prosthetic valvular endocarditis
- Right-sided endocarditis
- Noninfective Endocarditis
- Hypertension/Hypotension
- Pericardial Disease
- Shock
- Hypovolemic shock
- Vasodilatory shock
- Cardiogenic shock
- Valvular Heart Disease
- Vascular Disease
CHAPTER THREE: Demographics and Epidemiology
- Background
- Population Demographics
- Epidemiology and Pathology of Cardiovascular Diseases
- Cardiomyopathy/Congestive Heart Failure (CHF)
- Types of Heart Failure
- Left Ventricular (LV) Failure
- Right Ventricular (RV) Failure
- Systolic Dysfunction
- Diastolic Dysfunction
- High Output Failure
- Theories of Congestive Heart Failure
- Hemodynamic Response Theory
- Neurohormonal Response Theory
- Renal Response Theory
- Conditions Leading to Congestive Heart Failure
- Arrhythmias
- Arteriosclerosis/Atherosclerosis
- Heart Valve Disease
CHAPTER FOUR: Therapeutic Cardiovascular Devices
- Overview
- Prosthetic Heart Valves
- Pacemakers
- Implantable Cardioverter-Defibrillators (ICDs)
- Ventricular Assist Devices (VADs)
- Total Artificial Heart Devices (TAHs)
- Coronary Artery Stents
- Cardiac Support Devices
CHAPTER FIVE: Market Analysis
- Market Size and Growth Overview
- Cardiomyopathy/Congestive Heart Failure (CHF)
- Arrhythmia
- Arteriosclerosis
- Heart Valve Diseases
- The 45+-Year-Old Market: A General View
- Cardiomyopathy/Congestive Heart Failure
- Arrhythmias
- Arteriosclerosis
- Valvular Heart Disease
- Competitive Outlook
- Market Trends
CHAPTER SIX: Company Profiles
- Overview
- Abbott Vascular Devices Division of Abbott Laboratories
- Abiomed, Inc.
- Acorn Cardiovascular, Inc.
- Arrow International
- Boston Scientific Corp.
- Cordis Corporation (A Johnson & Johnson Company)
- Guidant Corporation A Johnson & Johnson Company
- Medtronic, Inc.
- Cardiac Rhythm Management (CRM)
- Vascular
- Cardiac Surgery
- MicroMed Technology, Inc.
- Myocor, Inc.
- St. Jude Medical
- Somanetics Corporation
- Somanetics Corporation
- Thoratec Corporation
Chapter Seven: Conclusions and Strategic Implications
- First Conclusion
- Implications:
- Second Conclusion
- Implications:
- Third Conclusion
- Implications:
- Fourth Conclusion
- Implications:
- Fifth Conclusion
- Implications:
- Sixth Conclusion
- Implications:
- Seventh Conclusion
- Implications:
- Eighth Conclusion
- Implications:
- Ninth Conclusion
- Implications:
- Tenth Conclusion
- Implications:
- Eleventh Conclusion
- Implications:
- Twelfth Conclusion
- Implications:
- Thirteenth Conclusion
- Implications:
APPENDIX A: Company Directory
APPENDIX B: Glossary
List of Exhibits
CHAPTER ONE: Executive Summary
- Table 1-1: Prevalence of Selected Cardiovascular Diseases in the United States for the Total Population and Those 45 Years of Age and Older 2004-2014
- Figure 1-1: Trending in United States Cardiovascular Disease Prevalence in the General Population and the 45+ Year Old Age Group 2004 – 2014
- Figure 1-2: Trending in U.S. Cases of Cardiomyopathy/Congestive Heart Failure 2004-2014
- Figure 1-3: Trending in U.S. Cases of Arrhythmia 2004-2014
- Figure 1-4: Trending in United States Cases of Arteriosclerosis (Coronary Artery Disease): 2004-2014
- Figure 1-5: Trending in U.S. Cases of Valvular Heart Disease 2004-2014
- Table 1-2: The Projected U.S. Total Available Market Potential of Therapeutic Devices for Cardiovascular Diseases by Type (Congestive Heart Failure, Arrhythmia, Arteriosclerosis and Heart Valve Disease) in the General Population and the Population Aged 45 Years and Older 2004-2014
- Figure 1-6: The Projected U.S. Total Available Market Potential of Therapeutic Devices for Cardiovascular Diseases in the General Population and the Population Aged 45 Years and Older 2004-2014
- Table 1-3: Key Competitors in the Therapeutic Cardiovascular Device Markets
CHAPTER tWO: Overview of Cardiovascular Disease
- Table 2-1: Benign and Malignant Cardiac Tumors
- Table 2-2: Common Contributors to Congestive Heart Failure
CHAPTER THREE: Demographics and Epidemiology
- Figure 3-1: Growth of the World’s Elderly (60+ Years) Population 2001 – 2025
- Figure 3-2: Population Distribution of the United States by Age and Sex for 2000, 2005 and 2010
- Figure 3-3: The Growing United States Population: 2004-2014
- Figure 3-4: Projected Increasing Median Age of the United States Population: 2004-2014
- Figure 3-5: Projected Increasing Mean Age of the United States Population: 2004-2014
- Table 3-1: Prevalence of Selected Cardiovascular Diseases (CVD) in the United States for the Total Population and Those 45 Years of Age and Older: 2004 – 2014
- Figure 3-6: Trending in United States Selected Cardiovascular Disease (CVD) Cases in the General Population and the 45+ Year Old Age Group: 2004 – 2014
- Table 3-2: Prevalence Statistics for Different Types of Cardiomyopathy in the United States
- Table 3-3: Common Contributors to Congestive Heart Failure
- Table 3-7: Trending in the Prevalence of Cardiomyopathy/Congestive Heart Failure in the United States (Total Population and Those Aged 45 Year and Older) 2004-2014
- Table 3-4: Types of Arrhythmias
- Table 3-5: Prevalence Statistics for Types of Arrhythmias in the United States (22 types)
- Table 3-8: Trending in the Prevalence of Arrhythmia in the United States (Total Population and Those Aged 45 Year and Older) 2004-2014
- Table 3-9: Trending in the Prevalence of Arteriosclerosis (CAD) in the United States (Total Population and Those Aged 45 Year and Older) 2004-2014
- Table 3-10: Trending in the Prevalence of Heart Valve Disease in the United States (Total Population and Those Aged 45 Year and Older) 2004-2014
CHAPTER FOUR: Therapeutic Cardiovascular Devices
- Table 4-1: Key Providers of Prosthetic Heart Valves
- Table 4-2: Key Providers of Pacemakers
- Table 4-3: Key Providers of ICDs
- Table 4-4: Key Providers of VADs
- Table 4-5: Key Providers of TAHs
- Table 4-6: Candidate Drugs for Drug-Eluting Stents
- Table 4-7: Companies Active in Drug-Eluting Stent Commercialization
- Table 4-8: Key Providers of Cardiac Support Devices
CHAPTER FIVE: Market Analysis
- Table 4-1: The Projected U.S. Total Available Market Potential for Therapeutic Devices by Condition (Arteriosclerosis, Cardiomyopathy/Congestive Heart Failure, Arrhythmia and Heart Valve Disease) 2004-2014
- Figure 4-1: Trending in the Projected U.S. Total Available Market Potential Therapeutic Devices by Condition (Arteriosclerosis, Cardiomyopathy/Congestive Heart Failure, Arrhythmia and Heart Valve Disease) 2004-2014
- Figure 4-2: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices Used for the Treatment of Cardiomyopathy/Congestive Heart Failure 2004-2014
- Figure 4-3: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Arrhythmias 2004-2014
- Figure 4-4: Trending in the Projected U.S. Total Available Market Potential for the Therapeutic Cardiovascular Devices in the Treatment of Arteriosclerosis 2004-2014
- Figure 4-5: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Heart Valve Diseases 2004-2014
- Table 4-2: The Projected U.S. Total Available Market Potential for Therapeutic Devices in the 45+ Year Old Age Group by Condition (Arteriosclerosis, Cardiomyopathy/Congestive Heart Failure, Arrhythmia, and Heart Valve Disease) 2004-2014
- Figure 4-6: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Devices in the 45+ Year Old Age Group by Condition (Arteriosclerosis, Cardiomyopathy/Congestive Heart Failure, Arrhythmia, and Heart Valve Disease) 2004-2014
- Figure 4-7: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Cardiomyopathy/Congestive Heart Failure in the 45+-Year-Old Population 2004-2014
- Figure 4-8: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Arrhythmias in the 45+-Year-Old Population 2004-2014
- Figure 4-9: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Arteriosclerosis in the 45+-Year-Old Population 2004-2014
- Figure 4-10: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Heart Valve Disease in the 45+-Year-Old Population 2004-2014
